EDIT shares moved up 13% today. A look at what's happening:

Shares of Editas Medicine (EDIT) are trading 13% higher at a price of $16.23 at the time of this writing. The stock rose sharply, caught up amidst a flurry of thematic buying in the biotech and CRISPR space with similar names like Bluebird Bio (BLUE), and CRISPR Therapeutics (CRSP)

Editas Medicine has been trading between a 52-week high of $73.03 and a 52-week low of $9.59. The stock has a market cap of $1.11 Billion.

As a leading genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cas12a (also known as Cpf1) genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases. For the latest information and scientific presentations, please visit www.editasmedicine.com.